§ 520.622d Diethylcarbamazine citrate capsules.
(a) Specifications. Each capsule contains 12.5, 50, 200, or 400 milligrams (mg) diethylcarbamazine citrate.
(b) Sponsor. See No. 011014 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount/indications for use. 3 mg per pound (lb) body weight daily for prevention of heartworm disease (Dirofilaria immitis); 25 to 50 mg/lb body weight in a single dose as an aid in the treatment of ascarid infections (Toxocara canis and Toxascaris leonina).
(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.623 Diethylcarbamazine citrate, oxibendazole chewable tablets.
(a) Specifications. Each tablet contains either 60, 120, or 180 milligrams of diethylcarbamazine citrate with 45, 91, or 136 milligrams of oxibendazole, respectively.
(b) Sponsor. See 000069 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. Administer orally to dogs at a dosage level of 6.6 milligrams of diethylcarbamazine citrate per kilogram of body weight (3 milligrams per pound of body weight) and 5.0 milligrams of oxibendazole per kilogram of body weight (2.27 milligrams per pound of body weight).
(2) Indications for use. For prevention of infection with Dirofilaria immitis (heartworm disease) and Ancylostoma caninum (hookworm infection) and for removal and control of Trichuris vulpis (whipworm infection) and mature and immature stages of intestinal Toxocara canis (ascarid infection).
(3) Limitations. Orally administer daily during heartworm season. For free-choice feeding or broken and placed on or mixed with feed. Do not use in dogs that may harbor adult heartworms. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.645 Difloxacin.
(a) Specifications. Each tablet contains 11.4, 45.4, or 136 milligrams (mg) of difloxacin hydrochloride.
(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(i) Amount. Administer 5 to 10 mg per kilogram (2.3 to 4.6 mg per pound) of body weight orally once a day for 2 to 3 days beyond cessation of clinical signs of disease up to a maximum of 30 days.
(ii) Indications for use. For management of diseases in dogs associated with bacteria susceptible to difloxacin.
(iii) Limitations. Federal law prohibits the extra-label use of this drug in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.666 Dirlotapide.
(a) Specifications. Each milliliter (mL) of solution contains 5 milligrams (mg) dirlotapide.
(b) Sponsor. See No. 000069 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. The initial dosage is 0.01 mL/kg (0.0045 mL/lb) body weight for the first 14 days. After the first 14 days of treatment, the dose volume is doubled to 0.02 mL/kg (0.009 mL/lb) body weight for the next 14 days (days 15 to 28 of treatment). Dogs should be weighed monthly and the dose volume adjusted every month, as necessary, to maintain a target percent weight loss until the desired weight is achieved.
(2) Indications for use. For the management of obesity.